Merck Highlights New Data from Leading Lung Cancer Clinical Development Program at the IASLC 2019 World Conference on Lung Cancer
Pooled Overall Survival (OS) Data from Three Trials with KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Subgroup of Patients with Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Do Not Express PD-L1
New KEYTRUDA Monotherapy Data in NSCLC Include Three-Year OS Data from Phase 3 KEYNOTE-024 and First-Time Data in Chinese Patients from Phase 3 KEYNOTE-042
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from the company’s leading clinical development program in lung cancer will be presented at the IASLC 2019 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer in Barcelona, Spain from Sept. 7-10, 2019. More than 30 abstracts evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with other cancer therapies and as monotherapy, will be presented.
Media Contacts:
Pamela Eisele
(267) 305-3558
Justine Moore
(347) 281-3754
Investor Contacts:
Peter Dannenbaum
(908) 740-1037
Michael DeCarbo
(908) 740-1807
